CD19嵌合抗原受体T细胞治疗后细胞因子释放综合征的诊治进展

Progress of diagnosis and treatment of cytokine release syndrome after CD19 chimeric antigen receptor T cells therapy

CD19嵌合抗原受体T细胞疗法是治疗B细胞血液肿瘤的新兴免疫疗法,并取得了较好的疗效。随着其使用的增加,免疫效应细胞相关细胞因子释放综合征的发生率也相应升高,迫切需要对其精确机制和治疗进行进一步的临床研究。文章总结了细胞因子释放综合征的机制、临床表现、分级系统、治疗以及管理策略。

CD19 chimeric antigen receptor T cells(CAR-T)therapy is a new immunotherapy for B-cell hematological tumors,and has good efficacy.With the increase of its use,the incidence of immune effector cell-associated cytokine release syndrome is increasing,and further clinical research on its precise mechanism and treatment is urgently needed.This review summarizes the mechanisms,clinical manifestations,grading systems,treatments and management strategies of cytokine release syndrome.